GB201614834D0 - Treatment of dementia - Google Patents
Treatment of dementiaInfo
- Publication number
- GB201614834D0 GB201614834D0 GBGB1614834.8A GB201614834A GB201614834D0 GB 201614834 D0 GB201614834 D0 GB 201614834D0 GB 201614834 A GB201614834 A GB 201614834A GB 201614834 D0 GB201614834 D0 GB 201614834D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- dementia
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Valve Device For Special Equipments (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
| DK17761842.8T DK3506904T3 (da) | 2016-09-01 | 2017-08-25 | Behandling af demens |
| EP17761842.8A EP3506904B1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
| KR1020197009175A KR102559354B1 (ko) | 2016-09-01 | 2017-08-25 | 치매 치료 |
| PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
| CA3034625A CA3034625C (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
| MX2019002429A MX384442B (es) | 2016-09-01 | 2017-08-25 | Tratamiento de la demencia. |
| ES17761842T ES2847929T3 (es) | 2016-09-01 | 2017-08-25 | Tratamiento de la demencia |
| HRP20210162TT HRP20210162T1 (hr) | 2016-09-01 | 2017-08-25 | Liječenje demencije |
| PT177618428T PT3506904T (pt) | 2016-09-01 | 2017-08-25 | Tratamento de demência |
| MYPI2019001119A MY187564A (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
| JP2019511720A JP7066679B2 (ja) | 2016-09-01 | 2017-08-25 | 認知症の処置 |
| SG11201901125TA SG11201901125TA (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
| CN201780067154.4A CN109890391B (zh) | 2016-09-01 | 2017-08-25 | 痴呆症的治疗 |
| AU2017318333A AU2017318333B2 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
| SI201730630T SI3506904T1 (sl) | 2016-09-01 | 2017-08-25 | Zdravljenje demence |
| PL17761842T PL3506904T3 (pl) | 2016-09-01 | 2017-08-25 | Leczenie otępienia |
| US16/329,611 US10842796B2 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201614834D0 true GB201614834D0 (en) | 2016-10-19 |
Family
ID=57139937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1614834.8A Ceased GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10842796B2 (https=) |
| EP (1) | EP3506904B1 (https=) |
| JP (1) | JP7066679B2 (https=) |
| KR (1) | KR102559354B1 (https=) |
| CN (1) | CN109890391B (https=) |
| AU (1) | AU2017318333B2 (https=) |
| DK (1) | DK3506904T3 (https=) |
| ES (1) | ES2847929T3 (https=) |
| GB (1) | GB201614834D0 (https=) |
| HR (1) | HRP20210162T1 (https=) |
| MX (1) | MX384442B (https=) |
| MY (1) | MY187564A (https=) |
| PL (1) | PL3506904T3 (https=) |
| PT (1) | PT3506904T (https=) |
| SG (1) | SG11201901125TA (https=) |
| SI (1) | SI3506904T1 (https=) |
| WO (1) | WO2018041739A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| MY148145A (en) | 2006-07-11 | 2013-03-15 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| JP7073330B2 (ja) | 2016-07-25 | 2022-05-23 | ウィスタ ラボラトリーズ リミテッド | ジアミノフェノチアジンの投与及び投与量 |
| FI4385512T3 (fi) | 2018-07-26 | 2026-01-12 | Taurx Therapeutics Man Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
| EP3847664A1 (en) | 2018-09-05 | 2021-07-14 | Genting Taurx Diagnostic Centre SDN BHD | Network methods for neurodegenerative diseases |
| GB201909493D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| MX2022013884A (es) * | 2020-05-05 | 2022-11-30 | Wista Lab Ltd | Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia. |
| GB202006659D0 (en) * | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| AU2023279800A1 (en) | 2022-05-31 | 2024-12-19 | TauRx Therapeutics Management Ltd | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| AU2024224306A1 (en) * | 2023-02-21 | 2025-09-11 | Prosetta Biosciences, Inc. | Phenothiazinyl compounds and uses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| PT1509232E (pt) * | 2002-05-31 | 2009-01-07 | Lundbeck & Co As H | Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer |
| SI2322517T1 (sl) | 2004-09-23 | 2019-06-28 | Wista Laboratories Ltd. | Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC) |
| WO2007110630A1 (en) | 2006-03-29 | 2007-10-04 | Wista Laboratories Ltd. | Thioninium compounds and their use |
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| MY148145A (en) | 2006-07-11 | 2013-03-15 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| AU2008265045B2 (en) * | 2007-06-19 | 2014-02-27 | Taurx Therapeutics Management Ltd. | Phenothiazine compounds for treating Mild Cognitive Impairment |
| CA2701075C (en) | 2007-10-03 | 2019-02-12 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines. |
| JP5918136B2 (ja) * | 2009-09-24 | 2016-05-18 | ウィスタ ラボラトリーズ リミテッド | プロセス |
| MX355627B (es) | 2009-09-24 | 2018-04-25 | Wista Lab Ltd | Clorhidratos de metiltioninio (azul de metileno) cristalinos. |
| JP5898701B2 (ja) * | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| CN102936244B (zh) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | 一种他克林-吩噻嗪异二联体类化合物及其制备方法 |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 HR HRP20210162TT patent/HRP20210162T1/hr unknown
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/da active
- 2017-08-25 MX MX2019002429A patent/MX384442B/es unknown
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/zh active Active
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/ko active Active
- 2017-08-25 PL PL17761842T patent/PL3506904T3/pl unknown
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en not_active Ceased
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/ja active Active
- 2017-08-25 PT PT177618428T patent/PT3506904T/pt unknown
- 2017-08-25 ES ES17761842T patent/ES2847929T3/es active Active
- 2017-08-25 SI SI201730630T patent/SI3506904T1/sl unknown
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10842796B2 (en) | 2020-11-24 |
| MX384442B (es) | 2025-03-14 |
| ES2847929T3 (es) | 2021-08-04 |
| US20190192530A1 (en) | 2019-06-27 |
| KR20190045273A (ko) | 2019-05-02 |
| MY187564A (en) | 2021-09-30 |
| JP2019526571A (ja) | 2019-09-19 |
| CA3034625A1 (en) | 2018-03-08 |
| EP3506904B1 (en) | 2020-12-09 |
| JP7066679B2 (ja) | 2022-05-13 |
| WO2018041739A1 (en) | 2018-03-08 |
| CN109890391A (zh) | 2019-06-14 |
| SI3506904T1 (sl) | 2021-03-31 |
| MX2019002429A (es) | 2019-07-08 |
| DK3506904T3 (da) | 2021-01-04 |
| CN109890391B (zh) | 2023-01-31 |
| KR102559354B1 (ko) | 2023-07-26 |
| HRP20210162T1 (hr) | 2021-03-19 |
| PL3506904T3 (pl) | 2021-07-26 |
| EP3506904A1 (en) | 2019-07-10 |
| AU2017318333A1 (en) | 2019-04-18 |
| SG11201901125TA (en) | 2019-03-28 |
| PT3506904T (pt) | 2021-02-02 |
| AU2017318333B2 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006746B (en) | Methods of treatment | |
| IL279627A (en) | A method for treating depression | |
| PL3506904T3 (pl) | Leczenie otępienia | |
| GB201701673D0 (en) | Methods of well treatment | |
| IL267253A (en) | Methods for treating cochlear synaptopathy | |
| GB201608885D0 (en) | Treatment | |
| IL290855A (en) | Treatment methods using vitamin d | |
| GB201410116D0 (en) | Method of treatment | |
| PT3377064T (pt) | Orvepitante para o tratamento da tosse crónica | |
| IL253028A0 (en) | treatment method | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| GB201603546D0 (en) | Treatment of urine | |
| IL260094A (en) | Treatment of hand eczema | |
| PT3504163T (pt) | Tratamento de águas residuais | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| GB201602802D0 (en) | Method of treatment | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201510870D0 (en) | Treatment of infarction | |
| GB201608599D0 (en) | Treatment of opioid tollerence | |
| GB201613350D0 (en) | Treatment of hyperpigmentation | |
| GB201617107D0 (en) | Treatment | |
| GB201612260D0 (en) | Treatment | |
| GB201612193D0 (en) | Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |